Substance / Medication

Temozolomide

Overview

Active Ingredient
temozolomide
RxNorm CUI
37776
Labeler: Sun Pharmaceutical Industries, Inc.Updated: 2025-11-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Temozolomide is contraindicated in patients with a history of serious hypersensitivity reactions to: [see Adverse Reactions (6.2)]. Reactions to temozolomide have included anaphylaxis temozolomide or any other ingredients in temozolomide capsules; and dacarbazine, since both temozolomide and dacarba

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

23 trials linked to this intervention

23
Total Trials
20
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The role of miRNA-10b and miRNA-21 in radioresistance and temozolomide resistance of high-grade glioma patients: a systematic review.
Hartanto Rachmat A, Malueka Rusdy G, Tamba Daniel A et al. · Neurosurg Focus · 2025
PMID: 40749245Meta-Analysis
The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
Inggas Made Agus Mahendra, Patel Utsav, Wijaya Jeremiah Hilkiah et al. · BMC Cancer · 2025
PMID: 40045273Meta-AnalysisFull text (PMC)
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.
Chen Lu, Cai Beichen, Ni Xuejun et al. · Melanoma Res · 2025
PMID: 39874124Meta-Analysis
A systematic review of immunotherapies in combination with temozolomide as treatment for glioblastoma.
Chen Brendan, Alder Janet · Cancer Treat Res Commun · 2025
PMID: 40023003Meta-Analysis
Metformin as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A Systematic Review and Meta-Analysis.
Bittencurt Thomaz de Assis Eloísa, Ferreira Marcio Yuri, Sales de Oliveira Jéssica et al. · World Neurosurg · 2025
PMID: 40023279Meta-Analysis
Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Taherifard Erfan, Bakhtiar Muhammad, Mahnoor Mahnoor et al. · BMC Cancer · 2024
PMID: 38347461Meta-AnalysisFull text (PMC)
Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis.
Ferreira Marcio Yuri, Thomaz de Assis Eloísa Bittencurt, Batista Savio et al. · World Neurosurg · 2024
PMID: 38184227Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Temozolomide (substance)
SNOMED CT
387009002
UMLS CUI
C0076080
RxNorm CUI
37776
Labeler
Sun Pharmaceutical Industries, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
23
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.